

**AMENDMENTS TO THE CLAIMS**

1-2. (Canceled).

3. (Withdrawn) A polynucleotide having a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 46, 47, 49, 51, 53, 55, 57, 58, 60, 62, 64, 66, 68, 70, 72, and 74.

4. (Currently Amended) A method for diagnosing ~~diagnostic kit for solid~~ primary esophageal cancer comprising ~~a means of~~ detecting the expression of at least one human ~~solid~~ esophageal cancer antigenic polypeptide in a sample ~~derived from a subject~~, characterized in that the human ~~solid~~ esophageal cancer antigenic polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 48, 50, 52, 54, 56, 59, 61, 63, 65, 67, 69, 71, 73, and 75.

5. (Currently Amended) A method for diagnosing ~~diagnostic kit for solid~~ primary esophageal cancer comprising ~~a means of~~ detecting the expression of at least one human ~~solid~~ esophageal cancer antigenic polypeptide in a sample ~~derived from a subject~~, characterized in that the human ~~solid~~ esophageal cancer antigenic polypeptide is encoded by a polynucleotide having a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 46, 47, 49, 51, 53, 55, 57, 58, 60, 62, 64, 66, 68, 70, 72, and 74.

6. (Currently Amended) The method for diagnosing diagnostic kit for solid primary esophageal cancer according to claim 4, wherein ~~the means of detecting~~ the detection of expression of the human ~~solid~~ esophageal cancer antigenic polypeptide is determined by detecting an antibody against the esophageal cancer antigenic polypeptide in the sample using the solid esophageal cancer antigenic polypeptide or a partial peptide thereof.

7. (Currently Amended) The method for diagnosing diagnostic kit for solid primary esophageal cancer according to claim 4, wherein ~~the means of detecting~~ the detection of expression of the human ~~solid~~ esophageal cancer antigenic polypeptide is determined by detecting the esophageal cancer antigenic polypeptide in the sample using an antibody against the esophageal-solid cancer antigenic polypeptide.

8. (Withdrawn) The diagnostic kit for solid cancer according to claim 4, wherein the means of detecting the expression of the human solid cancer antigenic polypeptide is a primer or probe comprising a polynucleotide consisting of the entire or a partial sequence of a polynucleotide encoding the solid cancer antigenic polypeptide or a complementary sequence thereof.

9. (Currently Amended) The method for diagnosing diagnostic kit for solid primary esophageal cancer according to claim ~~[[4]]~~ 6, wherein the esophageal cancer antigenic polypeptide or the antibody ~~means of detecting the expression of the human solid cancer antigenic polypeptide~~ is immobilized on a solid phase.

10. (Currently Amended) The method for diagnosing ~~diagnostic kit for solid~~ primary esophageal cancer according to claim ~~[[4]]~~ 6, wherein the esophageal cancer antigenic polypeptide or the antibody ~~means of detecting the expression of the human solid cancer antigenic polypeptide~~ is labeled.

11. (Canceled).

12. (Currently Amended) The method for diagnosing ~~diagnostic kit for solid~~ primary esophageal cancer according to claim 4, wherein the sample is selected from the group consisting of ~~serum, blood, hemocytes, and tissue~~ serum and blood.

13-17. (Canceled).

18. (Withdrawn) A medicament for preventing or treating solid cancer comprising a gene encoding a prophylactic or therapeutic agent for solid cancer and a means of targeting to human solid cancer.

19. (Withdrawn) The medicament according to claim 18, wherein the means of targeting to human solid cancer is an antibody against a solid cancer antigenic polypeptide.

20. (Withdrawn) The medicament according to claim 18, wherein the means of targeting to human solid cancer is a nucleotide sequence of an expression control region of a polynucleotide encoding a solid cancer antigenic polypeptide.

21. (New) The method for diagnosing primary esophageal cancer according to claim 7, wherein the esophageal cancer antigenic polypeptide or the antibody is immobilized on a solid phase.

22. (New) The method for diagnosing primary esophageal cancer according to claim 7, wherein the esophageal cancer antigenic polypeptide or the antibody is labeled.